GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Take Ltd

TAKE Ltd: H1 FY27 Consolidated Total Income ₹615.54 Million, Returns to Profitability

RESULTS ▲ Positive Development MEDIUM RISK
📅 Filed on BSE: 13 Nov 2026, 07:00 PM IST  ·  BSE ID: 733e75af-a6f0-45b9-ab13-345ddefa61d5
View Original BSE Filing (PDF)
💡
In Simple Terms
The company made a profit in the first half of the financial year, driven by growth in its healthcare and tech segments.
🤖 AI Summary
  • Consolidated Total Income for H1 FY27 reached ₹615.54 Million for TAKE Limited.
  • Consolidated Profit After Tax (PAT) was ₹32.75 Million in H1 FY27, reversing a loss from H1 FY26.
  • Q2 FY27 consolidated Total Income stood at ₹298.52 Million, with Revenue from Operations at ₹294.17 Million.
  • Consolidated Net Profit for Q2 FY27 was ₹22.12 Million, marking 108.17% Q-o-Q growth from Q1 FY27.
  • The company launched TAKE.Health, an intelligent digital health companion, and a ₹50 Million Innovation Fund.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Consolidated Total Income (H1 FY27)
₹615.54 Million
Consolidated Profit After Tax (H1 FY27)
₹32.75 Million
Not comparable — limited prior period data.
Consolidated Loss After Tax (H1 FY26)
₹12.13 Million
Consolidated Total Income (Q2 FY27)
₹298.52 Million
Consolidated Net Profit (Q2 FY27)
₹22.12 Million
108.17%
Consolidated Net Profit (Q1 FY27)
₹10.63 Million
Innovation Fund Initial Corpus
₹50 Million
🏢 How This Affects the Company
📈
Business Impact
The company is advancing its strategic direction by launching TAKE.Health and establishing an Innovation Fund, focusing on digital healthcare, AI, and longevity sciences.
💰
Financial Impact
TAKE Limited returned to profitability, reporting consolidated PAT of ₹32.75 Million in H1 FY27, compared to a loss of ₹12.13 Million in H1 FY26.
⚙️
Operational Impact
New initiatives like TAKE.Health and the Innovation Fund will require resources for developing digital platforms, identifying startups, and exploring new markets in longevity and anti-ageing.
⚠️
Risk Impact
The strategic entry into new markets such as longevity and anti-ageing introduces risks associated with market acceptance and product development in these emerging sectors.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based on this financial results press release.
👤
Who Is Affected
All shareholders are affected by the company's financial performance, specifically the return to consolidated profitability with PAT of ₹32.75 Million in H1 FY27.
🔍
Management Signal
Management intends to focus on innovation-led growth in digital healthcare, AI, and longevity sciences, while strengthening financial fundamentals and execution capabilities.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Q3 FY27 financial results — check for sustained profitability and revenue growth.
Updates on TAKE.Health platform adoption and user engagement metrics.
Details on the first investments made by the ₹50 Million Innovation Fund.
MEDIUM RISK Entry into new, rapidly evolving markets like longevity sciences carries inherent execution and market adoption risks.
💡 Investor Takeaway
TAKE Limited reported consolidated Total Income of ₹615.54 Million for H1 FY27. Consolidated Net Profit reached ₹32.75 Million for H1 FY27, reversing a loss of ₹12.13 Million in H1 FY26. Q2 FY27 consolidated Net Profit was ₹22.12 Million, a 108.17% quarter-on-quarter growth.
⚖️ Strengths & Concerns

✅ Positives

  • Consolidated Net Profit of ₹32.75 Million in H1 FY27 marks a return to profitability from a loss of ₹12.13 Million in H1 FY26.
  • Q2 FY27 consolidated Net Profit grew 108.17% quarter-on-quarter to ₹22.12 Million from ₹10.63 Million in Q1 FY27.

⚠️ Concerns

  • No specific financial weaknesses are highlighted in the provided press release beyond the historical loss in H1 FY26.
  • The financial figures for the prior year's comparable period are not detailed enough to assess the scale of historical operations.
📅 Company Track Record
No previous filings or historical financial data for TAKE Limited were found in the context provided, preventing a comparative historical analysis of its performance trends.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was TAKE Limited's consolidated Total Income for H1 FY27?
TAKE Limited reported a consolidated Total Income of ₹615.54 Million for the half year ended September 30, 2026 (H1 FY27).
Did TAKE Limited achieve profitability in H1 FY27?
Yes, TAKE Limited returned to profitability with a consolidated Profit After Tax (PAT) of ₹32.75 Million for H1 FY27, compared to a loss of ₹12.13 Million in H1 FY26.
What was the consolidated Net Profit growth for TAKE Limited in Q2 FY27?
Consolidated Net Profit for Q2 FY27 increased to ₹22.12 Million, registering a 108.17% quarter-on-quarter growth over ₹10.63 Million in Q1 FY27.
What new strategic initiatives did TAKE Limited announce?
TAKE Limited launched TAKE.Health, an intelligent digital health companion, and a ₹50 Million Innovation Fund, along with strategic entry into India's longevity and anti-ageing market.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.

Live IPO, GMP and market updates on Telegram

IPO open and close dates, grey market premium moves, subscription figures, allotment and listing days, and the market updates worth knowing about, posted on the channel as they happen.

Join the channel